The historical rank and industry rank for Jazz Pharmaceuticals's Net Margin % or its related term are showing as below:
MEX:JAZZN'
s Net Margin % Range Over the Past 10 Years
Min: -10.65 Med: 12.3 Max: 30.14
Current: 0.66
MEX:JAZZN's Net Margin % is ranked better than 72.02% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs MEX:JAZZN: 0.66
Jazz Pharmaceuticals (MEX:JAZZN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Jazz Pharmaceuticals Net Margin % Related Terms
Jazz Pharmaceuticals Net Margin % Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:JAZZN vs ASND, SMMT, BBIO: Net Margin % Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (MEX:JAZZN) has a Net Margin % of 27.42% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Jazz Pharmaceuticals and its competitors. This is 123% above median its historical median of 12.30. According to the industry distribution chart, Jazz Pharmaceuticals ranks #265 out of 947 companies in the Biotechnology industry, placing it in the top 28%.
Is Jazz Pharmaceuticals' Net Margin % too high?
Jazz Pharmaceuticals' current Net Margin % of 27.42% is 123% above median its 10-year median of 12.30. Based on the distribution chart, Jazz Pharmaceuticals ranks #265 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Net Margin % compare to ASND and SMMT?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #265 out of 947 companies for Net Margin %. This puts Jazz Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Net Margin % is 27.42%, which is 123% above median its own 10-year median of 12.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Jazz Pharmaceuticals (MEX:JAZZN) has a current Net Margin % of 27.42%. The stock's GF Value™ is MXN1,641.59, compared to a current price of MXN2,500.00 — trading 52.3% above its estimated fair value. The current Net Margin % is 27.42%, which is 123% above median its 10-year median of 12.30. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Jazz Pharmaceuticals (MEX:JAZZN), the current Net Margin % is 27.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (MEX:JAZZN) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN2,500.00 is trading 52.3% above its estimated GF Value™ of MXN1,641.59.
Key valuation signals for MEX:JAZZN:
Net Margin %: 27.42% (123% above median its 10-year median of 12.30)
GF Value™: MXN1,641.59 vs. price of MXN2,500.00 (52.3% above fair value)
No single metric tells the full story. See the MEX:JAZZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for MEX:JAZZN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:JAZZN has been successfully added to your 
